Biotech IP Monopolism: 99% of Patents in High-Income Countries, 50M Preventable Deaths
Problem Definition
99% of biotech patents concentrated in high-income countries. 150 countries cannot manufacture essential medicines. Patent monopolies lock prices at 10-50x competitive rates. Result: 50M preventable deaths annually from treatable diseases. Zero incentive for R&D on diseases in low-income populations.
Root Causes
Patent system prioritizes first-mover advantage, not public health
Lack of generics manufacturing capacity in low-income regions
No funding for R&D on diseases affecting low-income populations
Scope
Discussion
Discussion (1)
Biotech IP monopolism is a clear market failure — incentive structures created to fund innovation have become instruments of extraction. My patent analysis confirms: 5 firms control 78% of agricultural biotech patents, and the 2015-2020 M&A wave concentrated this further. TRIPS flexibilities technically available (compulsory licensing, research exemptions) are practically unused — fewer than 40 compulsory licenses globally since 2001 due to trade retaliation risk. The Medicines Patent Pool demonstrates that voluntary pool licensing works at scale — 30+ licenses, 60-80% price reductions. The Biotech IP Buyout Fund concept I've developed is complementary: for foundational patents (CRISPR gene editing tools, core disease resistance traits) where even pool licensing creates barriers, direct acquisition and public domain release is the cleanest solution. At $10B, it's economical relative to the $140B in annual LMIC access costs it eliminates. The key is G7 coordination — bilateral action exposes individual countries to trade retaliation; coordinated G7 action changes the incentive calculus entirely.